ANDY SASSINE - 29 Jun 2018 Form 4 Insider Report for ICAD INC (ICAD)

Role
Director
Signature
/s/ Andy Sassine
Issuer symbol
ICAD
Transactions as of
29 Jun 2018
Transactions value $
$0
Form type
4
Filing time
09 Mar 2023, 20:32:23 UTC
Next filing
04 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICAD Director Stock Option (right to buy) Disposed to Issuer -6,219 -100% 0 29 Jun 2018 Common Stock 6,219 $3.05 Direct F1, F4
transaction ICAD Director Stock Option (right to buy) Award +6,219 6,219 07 Mar 2023 Common Stock 6,219 $3.05 Direct F1, F4
transaction ICAD Director Stock Option (right to buy) Disposed to Issuer -6,517 -100% 0 28 Sep 2018 Common Stock 6,517 $2.91 Direct F2, F4
transaction ICAD Director Stock Option (right to buy) Award +6,517 6,517 07 Mar 2023 Common Stock 6,517 $2.91 Direct F2, F4
transaction ICAD Director Stock Option (right to buy) Disposed to Issuer -9,321 -100% 0 31 Dec 2018 Common Stock 9,321 $3.7 Direct F3, F4
transaction ICAD Director Stock Option (right to buy) Award +9,321 9,321 07 Mar 2023 Common Stock 9,321 $3.7 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 29, 2018 and is fully vested as of the date hereof.
F2 The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 28, 2018 and is fully vested as of the date hereof.
F3 The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 31, 2018 and is fully vested as of the date hereof.
F4 On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option.